by admin | May 4, 2024 | Article
March 10, 2024 – Lupus Canada is pleased to share that Saphnelo has been listed in Manitoba effective April 1, 2024. For more information, please visit https://www.gov.mb.ca/health/mdbif/docs/bulletins/bulletin131.pdf
by admin | May 4, 2024 | Article
March 6, 2024 – Lupus Canada is pleased to share that Saphnelo has been listed in Nova Scotia effective March 1, 2024. The public notice and listing criteria will appear on the Nova Scotia Pharmacare Programs website when the March Bulletin is...
by admin | May 4, 2024 | Article
February 15, 2024 – Lupus Canada is honoured to be a member of the CIAN group. Together our goal is to protect more Canadians to improve the quality of life and significantly reduce hospitalization for vulnerable people. On page 60 of the Heal Canada Digital...
by admin | Apr 19, 2024 | Article
In a new study, researchers explored predictors of neuropsychiatric (brain-related) flare activity in people with lupus being treated with active disease (without ongoing or severe neuropsychiatric involvement), and found an association...
by admin | Apr 19, 2024 | Article
https://www.lupuscanada.org/wp-content/uploads/Immune-Compromised-Canadians-and-COVID-19.pdf
